Gilteritinib-d8

Modify Date: 2024-01-03 12:06:59

Gilteritinib-d8 structure	Common Name	Gilteritinib-d8
	CAS Number	2377109-74-3	Molecular Weight	560.76
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₉H₃₆D₈N₈O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Gilteritinib-d8

Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

Name	Gilteritinib-d8

Description	Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3 Signaling Pathways >> Protein Tyrosine Kinase/RTK >> TAM Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting. [3]. Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565.

Molecular Formula	C₂₉H₃₆D₈N₈O₃
Molecular Weight	560.76